Anirban Basu1, Willard G Manning. 1. Department of Medicine, Center for Health and the Social Sciences, University of Chicago, Chicago, Illinois, USA. abasu@medicine.bsd.uchicago.edu
Abstract
BACKGROUND: Given the characteristics of health care expenditure/cost data-a mass of observations at zero, and skewed positive expenditures, various alternative estimators have been developed that can address the analytical issues these characteristics raise. The field continues to develop new approaches and to evaluate the performance of the existing ones. OBJECTIVES: We discuss the strengths and limitations in existing methods for estimation and for model specification and checking. We suggest some areas that need fuller development or a better understanding of how the estimation approach performs when the outcome exhibits the skewness and heavy right tails that are typical of health care data. We also address various other aspects of cost analysis that include dealing with induced censoring, estimating casual effects, and generating reliable predictions that may apply to many studies. RESULTS: No current method is optimal or dominant for all cost applications. Many of the diagnostics used in choosing among alternatives have limitations that need more careful study. Several avenues in modeling cost data remain unexplored. CONCLUSIONS: Taken together, we hope that this essay would serve as a guide to the choice among methods and to the next generation of methodological research in this field.
BACKGROUND: Given the characteristics of health care expenditure/cost data-a mass of observations at zero, and skewed positive expenditures, various alternative estimators have been developed that can address the analytical issues these characteristics raise. The field continues to develop new approaches and to evaluate the performance of the existing ones. OBJECTIVES: We discuss the strengths and limitations in existing methods for estimation and for model specification and checking. We suggest some areas that need fuller development or a better understanding of how the estimation approach performs when the outcome exhibits the skewness and heavy right tails that are typical of health care data. We also address various other aspects of cost analysis that include dealing with induced censoring, estimating casual effects, and generating reliable predictions that may apply to many studies. RESULTS: No current method is optimal or dominant for all cost applications. Many of the diagnostics used in choosing among alternatives have limitations that need more careful study. Several avenues in modeling cost data remain unexplored. CONCLUSIONS: Taken together, we hope that this essay would serve as a guide to the choice among methods and to the next generation of methodological research in this field.
Authors: Joseph Lipscomb; K Robin Yabroff; Mark C Hornbrook; Anna Gigli; Silvia Francisci; Murray Krahn; Gemma Gatta; Annalisa Trama; Debra P Ritzwoller; Isabelle Durand-Zaleski; Ramzi Salloum; Neetu Chawla; Catia Angiolini; Emanuele Crocetti; Francesco Giusti; Stefano Guzzinati; Maura Mezzetti; Guido Miccinesi; Angela Mariotto Journal: J Natl Cancer Inst Monogr Date: 2013
Authors: Bohdan Nosyk; Viviane Lima; Guillaume Colley; Benita Yip; Robert S Hogg; Julio S G Montaner Journal: Pharmacoeconomics Date: 2015-03 Impact factor: 4.981
Authors: Anthony Waldron; Daniel C Miller; Dave Redding; Arne Mooers; Tyler S Kuhn; Nate Nibbelink; J Timmons Roberts; Joseph A Tobias; John L Gittleman Journal: Nature Date: 2017-10-25 Impact factor: 49.962
Authors: Jennifer L Lund; K Robin Yabroff; Yoko Ibuka; Louise B Russell; Paul G Barnett; Joseph Lipscomb; William F Lawrence; Martin L Brown Journal: Med Care Date: 2009-07 Impact factor: 2.983